Bayer CEO: "We need a predictable regulatory regime" for Roundup weedkiller
perigon
Last updated: April 16, 2026
Bayer CEO Bill Anderson has set a target for 2026 to resolve the ongoing controversy surrounding its Roundup weedkiller. This situation stems from Bayer's acquisition of Monsanto, the original developer of Roundup, which has led to numerous lawsuits alleging the product causes cancer.
- Bayer is aiming to settle the vast majority of Roundup-related litigation by 2026, a significant step towards moving past the costly legal battles. The company has faced substantial financial and reputational damage due to these lawsuits.
- The core of the legal challenges revolves around claims that glyphosate, the active ingredient in Roundup, is carcinogenic. Bayer acquired Monsanto in 2018, inheriting these legal liabilities.
- The company is reportedly considering various strategies to address these claims, including potential settlements and ongoing legal defenses. The resolution of these cases is crucial for Bayer's financial stability and future strategic direction.
- Anderson's statement indicates a proactive approach to definitively end the prolonged legal uncertainty that has impacted the company's stock performance and business operations. The outcome of these efforts will significantly shape Bayer's trajectory in the coming years.
